<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>2 Magnificent S&amp;P 500 Dividend Stocks Down 7% and 19% to Buy and Hold Forever â€” Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">2 Magnificent S&amp;P 500 Dividend Stocks Down 7% and 19% to Buy and Hold Forever</h2>
    <div class="badge">2025-09-20T17:25:00+00:00</div>
    <ul>
      <li>Management raised its 2025 revenue guidance and now expects better than 35% revenue growth, based on the midpoint of the $60 billion to $62 billion range.</li>
<li>Second-quarter revenue grew by 38%, and adjusted earnings per share increased 61% to $6.31.</li>
<li>It has three drugs, Mounjaro, Zepbound, and Verzenio, that account for 65% of its $15.6 billion second-quarter revenue.</li>
<li>It increased second-quarter research and development spending by 23% compared to a year ago, to $3.3 billion.</li>
<li>It&#x27;s the biggest expense item, representing more than 21% of revenue.</li>
<li>The products had top-line growth of 12% to 172%, and continue to drive revenue growth.</li>
<li>Second-quarter revenue, removing foreign-currency exchange fluctuations and acquisitions/divestitures, grew 5%.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=2%20Magnificent%20S%26P%20500%20Dividend%20Stocks%20Down%207%25%20and%2019%25%20to%20Buy%20and%20Hold%20Forever%0A%E2%80%A2%20Management%20raised%20its%202025%20revenue%20guidance%20and%20now%20expects%20better%20than%2035%25%20revenue%20growth%2C%20based%20on%20the%20midpoint%20of%20the%20%2460%20billion%20to%20%2462%20billion%20range.%0A%E2%80%A2%20Second-quarter%20revenue%20grew%20by%2038%25%2C%20and%20adjusted%20earnings%20per%20share%20increased%2061%25%20to%20%246.31.%0A%E2%80%A2%20It%20has%20three%20drugs%2C%20Mounjaro%2C%20Zepbound%2C%20and%20Verzenio%2C%20that%20account%20for%2065%25%20of%20its%20%2415.6%20billion%20second-quarter%20revenue.%0A%E2%80%A2%20It%20increased%20second-quarter%20research%20and%20development%20spending%20by%2023%25%20compared%20to%20a%20year%20ago%2C%20to%20%243.3%20billion.%0A%E2%80%A2%20It%27s%20the%20biggest%20expense%20item%2C%20representing%20more%20than%2021%25%20of%20revenue.%0A%E2%80%A2%20The%20products%20had%20top-line%20growth%20of%2012%25%20to%20172%25%2C%20and%20continue%20to%20drive%20revenue%20growth.%0A%E2%80%A2%20Second-quarter%20revenue%2C%20removing%20foreign-currency%20exchange%20fluctuations%20and%20acquisitions%2Fdivestitures%2C%20grew%205%25.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2F2-magnificent-s-p-500-dividend-stocks-down-7-and-19-to-buy-and-hold-forever%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/m/55bf6904-04ba-33b8-a85e-01ab2a5ca7f7/2-magnificent-s%26p-500.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>